Brief: Arcutis Canada Says Health Canada Approves ZORYVE Foam 0.3% For Scalp, Body Psoriasis For Adults & Adolescents 12 & Older
13/11/2025 13:22
Nov 13 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O: ARCUTIS CANADA: HEALTH CANADA APPROVES ZORYVE FOAM 0.3% FOR SCALP, BODY PSORIASIS FOR ADULTS & ADOLESCENTS AGES 12 & OLDER CANADA NEWSWIRE ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Canada Przoryve Cream 0.05% Receives Health Canada Approval For Atopic Dermatitis
Arcutis Biotherapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Arcutis Q2 revenue rises on demand for ZORYVE, lifts 2026 sales outlook
Arcutis Biotherapeutics Inc expected to post earnings of 4 cents a share - Earnings Preview
Brief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4